AML-302 Impact of Body Mass Index on Complete Remission Rates in Patients With Acute Myeloid Leukemia

Abstract

The impact of body mass index (BMI) on the outcomes of patients with acute myeloid leukemia (AML) has been assessed in different studies. However, the results remain controversial. The aim of our study was to assess the impact of BMI on the response to induction chemotherapy in adult patients with newly diagnosed AML. Our study enrolled 140 patients with AML. The data were collected from electronic medical records at the Oncology Center of Mansoura University. The patients were further classified according to BMI into those with normal BMI (40 patients), overweight (42 patients), and obese patients (58 patients). All patients received induction chemotherapy with 3+7 protocol (3 days of anthracycline and 7 days of cytarabine). Among the 40 patients with normal BMI, 25 patients (62.5%) achieved complete remission (CR), 7 patients (17.5%) died, and 8 patients (20%) were refractory to induction chemotherapy. Among those 8 patients, 7 received salvage chemotherapy with 4 patients achieving CR and 3 deaths. Regarding the 42 overweight patients, 14 patients (33.3%) attained CR, 22 patients (52.4%) died, and 6 patients (14.3%) remained refractory. After salvage chemotherapy, 3 patients achieved CR and 3 patients died. When it comes to the 58 obese patients, 27 patients (46.6%) achieved CR, 26 patients (44.8%) died, and 5 patients were refractory. Four of those refractory patients received salvage chemotherapy, and all died. Regarding CR rates after induction chemotherapy, our study concluded that CR rates are higher in patients with normal BMI compared to overweight and obese patients (95% CI, P=0.004). A larger, prospective randomized trial would be required to confirm these results.